Novavax (NVAX) 1.36 -0.06

Novavax, Inc.
(NVAX) 1.36 -0.06

Last Trade:	1.35	Day Range:	1.35 - 1.42
Trade Time:	08:02PM	52wk Range:	1.13 - 3.50
Prev. Close:	1.41	Market Cap:	155.21M
Open:	1.41	Div Yield:	0
Volume:	534900	PE:
EPS:	-0.18

The Latest On NVAX

Scorecard and New Picks: Technical Value Fishing Under $5 1/26/12 7:18am

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12 1:19pm

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12 1:18pm

Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High 1/23/12 11:20am

UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico 1/23/12 11:00am

Oink Oink: Profit From The Return Of Swine Flu 1/12/12 1:40pm

NOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals 1/3/12 8:06am

NOVAVAX Announces Contract Award from U.S. Department of Homeland Security to Develop Foot-and-Mouth Disease Vaccine 10/5/11 7:03am

NOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate 10/3/11 7:01am

NOVAVAX Announces Publication of Results From H5N1 Influenza Virus-Like Particle Vaccine Phase I/IIa Clinical Trial 9/8/11 7:04am

The Avian Flu is Back? Maybe We Can Do Something About It! 8/31/11 1:23pm

MLV Comments On New H5N1 Bird Flu Vaccine 8/31/11 8:36am

Scorecard and New Picks: Technical Value Fishing Under $5 1/26/12

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12

Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High 1/23/12

UPDATE: Novavax, Hemispherx BioPharma, Biocryst Spiking Higher on H1N1 Reports in Mexico 1/23/12

Oink Oink: Profit From The Return Of Swine Flu 1/12/12

NOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals 1/3/12

NOVAVAX Announces Contract Award from U.S. Department of Homeland Security to Develop Foot-and-Mouth Disease Vaccine 10/5/11

NOVAVAX Reports Positive Results From Phase I Trial of Respiratory Syncytial Virus Vaccine Candidate 10/3/11

NOVAVAX Announces Publication of Results From H5N1 Influenza Virus-Like Particle Vaccine Phase I/IIa Clinical Trial 9/8/11

The Avian Flu is Back? Maybe We Can Do Something About It! 8/31/11

MLV Comments On New H5N1 Bird Flu Vaccine 8/31/11

Swine Flu Has BioPharma as Happy as Pigs in Filth 1/23/12

Swine Flu Outbreak in Mexico Sends Small BioPharma Sky-High 1/23/12

Oink Oink: Profit From The Return Of Swine Flu 1/12/12

The Avian Flu is Back? Maybe We Can Do Something About It! 8/31/11

How Hysteria Kills The Market (NVAX) 1/26/11

Benzinga’s Top Pre-Market NASDAQ Losers (MNKD, MAIN, NVAX, QGEN) 8/17/10

Benzinga’s Top Pre-Market NASDAQ Gainers (RMBS, CYTX, NVAX, TLAB) 7/27/10

Benzinga’s Top Pre-Market Gainers (LIOX, SBCF, AUTH, NVAX, VICL) 4/22/10

Benzinga’s Top Pre- Market Gainers (TSTC, CTCM, SEED, GSIT, MITI, NVAX, NVMI, SPLS) 12/1/09

Benzinga’s Top Pre- Market Gainers (PDLI, NVAX, SIMG, ALTH, SEED, SQNM, VVUS) 11/30/09

Novavax, Inc. (NVAX) Up Big on Positive Clinical Trial Results 9/1/09

The Avian Flu is Back? Maybe We Can Do Something About It! 8/31/11

MLV Comments On New H5N1 Bird Flu Vaccine 8/31/11

UPDATE: MLV Reiterates Buy on Novavax, Reduces PT to $9.50 8/12/11

Novavax Granted HHS Contract for VLP Vaccine (NVAX) 3/28/11

KeyBank Downgrades Newmarket To Hold 3/15/11

Wedbush Initiates Coverage Of Novavax With Outperform Rating And $6 Price Target 3/15/11

Novavax Awarded BARDA Contract, Increasing Target to $4 3/1/11

Piper Jaffray Raises PT On Novavax To $4 3/1/11

Benzinga’s Top Pre-Market NASDAQ Losers (MNKD, MAIN, NVAX, QGEN) 8/17/10

Noravax's VLP Vaccine Closer To IND Filing 8/13/10

NVAX – A Novel Pure Play Vaccine Company 12/1/09

Novavax Inc (NASDAQ:NVAX) Massive Head & Shoulders Formation 11/2/09

Trade NVAX
NOW!

Partner Headlines

Novavax Narrows Loss - Analyst Blog 3/31/11

10 Stocks Under $4 With Upside 3/16/11

Sonus Networks, Novavax: Small-Cap Winner 3/1/11

Novavax, YRC Worldwide: After-Hours Trading 2/28/11

Novavax's Charts Look Healthy 12/30/10

MTR Gaming, Novavax: Early Volume Plays 3/15/10

Retail Sales: Tomorrow's Headliners 3/11/10

Novavax Inc. Reports Operating Results (10-Q)

Novavax Inc. (NVAX) CEO Stanley C Erck buys 13,000 Shares

Press Releases

NOVAVAX to Present at the 14th Annual Bio CEO & Investor Conference 2/10/12 GlobeNewswire Story

NOVAVAX Appoints Mervyn L. Hamer, Vice President of Manufacturing 2/1/12 GlobeNewswire Story

NOVAVAX Reports Progress Under Joint Venture in India With Cadila Pharmaceuticals 1/3/12 GlobeNewswire Story

NOVAVAX to Present at 23rd Annual Piper Jaffray Health Care Conference 11/28/11 GlobeNewswire Story

NOVAVAX Acquires New Manufacturing and Office Facilities in Gaithersburg, MD 11/21/11 GlobeNewswire Story

NOVAVAX to Present at the Lazard Capital Markets 8th Annual Healthcare Conference 11/10/11 GlobeNewswire Story

NOVAVAX Appoints Russell "Rip" Wilson Senior Vice President of Business Development 11/7/11 GlobeNewswire Story

NOVAVAX Reports Third Quarter 2011 Financial Results 11/4/11 GlobeNewswire Story

NOVAVAX Appoints Erica S. Shane, Ph.D., Vice President, Process Development 11/3/11 GlobeNewswire Story

Immunovaccine Announces Appointment of John Trizzino as CEO 9/12/11 Marketwire Story

NOVAVAX Announces Contract Award from U.S. Department of Homeland Security to Develop Foot-and-Mouth Disease Vaccine 8/30/11 GlobeNewswire Story

Novavax to Report Top-Line Results From Phase I Respiratory Syncytial Virus Vaccine Clinical Trial on October 3rd at 5th Vaccine and ISV Annual Global Conference 8/30/11 GlobeNewswire Story

Get the latest NVAX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Novavax, Inc. stock price.

Novavax, Inc. by YCharts

Novavax (NVAX) 1.36 -0.06

Quotes

Analysis

Twitter

Ownership

Earnings

The Latest On NVAX

From Benzinga's Newsdesk

Benzinga's News Delivered Free

Latest from Premium

Brain Trust

Popular Channels

Tools & Features

About Benzinga

Social